B. Freilich

TL;DR: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.

TL;DR: A 12‐week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated; there were no adverse events leading to discontinuation and only 1 serious AE on‐treatment, which was unrelated to study medications.

TL;DR: The findings lend support to the further assessment of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-naive patients with HCV genotype-1, and sustained virological response, defined as undetectable HCV RNA at post-treatment weeks 12 and 24.

TL;DR: PEG‐IFN alfa‐2b plus weight‐based RBV is more effective than flat‐dose RBV, particularly in genotype 1 patients, providing equivalent efficacy across all weight groups, and RBV 1400 mg/day is appropriate for patients 105 to 125 kg.

TL;DR: Oral GS-9620 was safe, well tolerated, and associated with induction of peripheral ISG15 production in the absence of significant systemic IFN-alpha levels or related symptoms in patients with chronic hepatitis B.